02126 PE Ratio & Valuation, Is 02126 Overvalued

Historical Valuation

JW THERAP-B (02126) is now in the Fair zone, suggesting that its current forward PS ratio of 3.49 is considered Fairly compared with the five-year average of -3.58. The fair price of JW THERAP-B (02126) is between 1.05 to 2.73 according to relative valuation method.

Relative Value

Fair Zone

1.05-2.73

Current Price：2.00

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is JW THERAP-B (02126) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

JW THERAP-B (02126) has a current Price-to-Book (P/B) ratio of 1.09. Compared to its 3-year average P/B ratio of 0.69, the current P/B ratio is approximately 58.76% higher. Relative to its 5-year average P/B ratio of 1.00, the current P/B ratio is about 9.28% higher. JW THERAP-B (02126) has a Forward Free Cash Flow (FCF) yield of approximately -22.27%. Compared to its 3-year average FCF yield of -47.33%, the current FCF yield is approximately -52.94% lower. Relative to its 5-year average FCF yield of -37.28%, the current FCF yield is about -40.25% lower.

Performance Decomposition

AI Analysis

Market capitalization of 02126 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 02126 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 02126 currently overvalued or undervalued?

What is JW THERAP-B (02126) fair value?

02126's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of JW THERAP-B (02126) is between 1.05 to 2.73 according to relative valuation method.

How does 02126's valuation metrics compare to the industry average?

The average P/S ratio for 02126's competitors is 0.00, providing a benchmark for relative valuation. JW THERAP-B Corp (02126) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for JW THERAP-B (02126) as of Mar 11 2026?

As of Mar 11 2026, JW THERAP-B (02126) has a P/B ratio of 1.09. This indicates that the market values 02126 at 1.09 times its book value.

What is the current FCF Yield for JW THERAP-B (02126) as of Mar 11 2026?

As of Mar 11 2026, JW THERAP-B (02126) has a FCF Yield of -22.27%. This means that for every dollar of JW THERAP-B's market capitalization, the company generates -22.27 cents in free cash flow.

What is the current Forward P/E ratio for JW THERAP-B (02126) as of Mar 11 2026?

As of Mar 11 2026, JW THERAP-B (02126) has a Forward P/E ratio of -2.53. This means the market is willing to pay $-2.53 for every dollar of JW THERAP-B's expected earnings over the next 12 months.

What is the current Forward P/S ratio for JW THERAP-B (02126) as of Mar 11 2026?

As of Mar 11 2026, JW THERAP-B (02126) has a Forward P/S ratio of 3.49. This means the market is valuing 02126 at $3.49 for every dollar of expected revenue over the next 12 months.

02126 Valuation